Status:
UNKNOWN
PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment
Lead Sponsor:
University of Warmia and Mazury
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18-87 years
Brief Summary
This is a retrospective study. The analysis includes patients with advanced neuroendocrine cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and metastasis, clinical, ...
Detailed Description
This is a retrospective study. The analysis includes patients with advanced neuroendocrine cancer (NEN) treated with systemic therapy, because of inoperable primary tumor or/and metastasis, clinical, ...
Eligibility Criteria
Inclusion
- Adults ≥18 years old, male or female,
- Patients with histopathological confirmation of advanced neuroendocrine cancer (NEN),
- Patients with NETG1, NETG2 based on Ki-67,
- Patients with diagnosed NEN, who did not receive prior treatment and were qualified to systemic treatment,
- Patients with advanced NEN who previously received first-line systemic therapy or second-line systemic therapy,
- Patients with advanced, inoperable NEN cancer before the treatment, during the treatment and after the treatment regardless of lines of systemic therapy,
- Patients with diagnosed NEN and performance status (PS) ≤3 according to ECOG/WHO classification, who received systemic therapy.
Exclusion
- Patients without histopathological confirmation of neuroendocrine carcinoma (NEN),
- Patients with diagnosed another type of cancer or benign tumor confirmed in histopathological examination,
- Patients treated prior with intention to treat (ITT),
- Patients with residual disease in further clinical follow-up without active systemic treatment,
- Patients with advanced, progressive and poor performance status, who were disqualified from further systemic treatment,
- Patients, who finished treatment during first month or their further disease process was unknown.
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04331912
Start Date
July 1 2019
End Date
December 31 2023
Last Update
May 13 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Warmia and Mazury in Olsztyn
Olsztyn, Warmian-Masurian Voivodeship, Poland, 10-082
2
Diagnostic and Therapy Center - Gammed
Warsaw, Poland, 02-351